Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania. Ostacher, M. J, Suppes, T., Swann, A. C, Eudicone, J. M, Landsberg, W., Baker, R. A, & Carlson, B. X International journal of bipolar disorders, 3:11, January, 2015. ![Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania. [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex BACKGROUND: A previous factor analysis of Young Mania Rating Scale and Montgomery-Åsberg Depression Rating Scale items identified composite factors of depression, mania, sleep disturbance, judgment/impulsivity, and irritability/hostility as major components of psychiatric symptoms in acute mania or mixed episodes in a series of trials of antipsychotics. However, it is unknown whether these factors predict treatment outcome. METHODS: Data from six double-blind, randomized, controlled clinical trials with aripiprazole in acute manic or mixed episodes in adults with bipolar I disorder were pooled for this analysis and the previously identified factors were examined for their value in predicting treatment outcome. Treatment efficacy was assessed for aripiprazole (n = 1,001), haloperidol (n = 324), lithium (n = 155), and placebo (n = 694) at baseline, days 4, 7, and 10, and then weekly to study end. Mean change in factor scores from baseline to week 3 was assessed by receiver operating characteristics curves for percentage factor change at day 4 and week 1. RESULTS: Subjects receiving aripiprazole, haloperidol, and lithium significantly improved mania factor scores versus placebo. Factors most predictive of endpoint efficacy for aripiprazole were judgment/impulsivity at day 4 and mania at week 1. Optimal factor score improvement for outcome prediction was approximately 40% to 50%. Early efficacy predicted treatment outcome across all factors; however, response at week 1 was a better predictor than response at day 4. CONCLUSIONS: This analysis confirms clinical benefits in early treatment/assessment for subjects with bipolar mania and suggests that certain symptom factors in mixed or manic episodes may be most predictive of treatment response.
@article{ostacher_patterns_2015,
title = {Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania.},
volume = {3},
issn = {2194-7511},
url = {http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4418976&tool=pmcentrez&rendertype=abstract},
doi = {10.1186/s40345-015-0026-0},
abstract = {BACKGROUND: A previous factor analysis of Young Mania Rating Scale and Montgomery-Åsberg Depression Rating Scale items identified composite factors of depression, mania, sleep disturbance, judgment/impulsivity, and irritability/hostility as major components of psychiatric symptoms in acute mania or mixed episodes in a series of trials of antipsychotics. However, it is unknown whether these factors predict treatment outcome.
METHODS: Data from six double-blind, randomized, controlled clinical trials with aripiprazole in acute manic or mixed episodes in adults with bipolar I disorder were pooled for this analysis and the previously identified factors were examined for their value in predicting treatment outcome. Treatment efficacy was assessed for aripiprazole (n = 1,001), haloperidol (n = 324), lithium (n = 155), and placebo (n = 694) at baseline, days 4, 7, and 10, and then weekly to study end. Mean change in factor scores from baseline to week 3 was assessed by receiver operating characteristics curves for percentage factor change at day 4 and week 1.
RESULTS: Subjects receiving aripiprazole, haloperidol, and lithium significantly improved mania factor scores versus placebo. Factors most predictive of endpoint efficacy for aripiprazole were judgment/impulsivity at day 4 and mania at week 1. Optimal factor score improvement for outcome prediction was approximately 40\% to 50\%. Early efficacy predicted treatment outcome across all factors; however, response at week 1 was a better predictor than response at day 4.
CONCLUSIONS: This analysis confirms clinical benefits in early treatment/assessment for subjects with bipolar mania and suggests that certain symptom factors in mixed or manic episodes may be most predictive of treatment response.},
urldate = {2015-05-10},
journal = {International journal of bipolar disorders},
author = {Ostacher, Michael J and Suppes, Trisha and Swann, Alan C and Eudicone, James M and Landsberg, Wally and Baker, Ross A and Carlson, Berit X},
month = jan,
year = {2015},
pmid = {25945321},
pages = {11},
}
Downloads: 0
{"_id":"KsmvRpsXu8kr52Yor","bibbaseid":"ostacher-suppes-swann-eudicone-landsberg-baker-carlson-patternsofresponsetoaripiprazolelithiumhaloperidolandplaceboacrossfactorscoresofmania-2015","author_short":["Ostacher, M. J","Suppes, T.","Swann, A. C","Eudicone, J. M","Landsberg, W.","Baker, R. A","Carlson, B. X"],"bibdata":{"bibtype":"article","type":"article","title":"Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania.","volume":"3","issn":"2194-7511","url":"http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4418976&tool=pmcentrez&rendertype=abstract","doi":"10.1186/s40345-015-0026-0","abstract":"BACKGROUND: A previous factor analysis of Young Mania Rating Scale and Montgomery-Åsberg Depression Rating Scale items identified composite factors of depression, mania, sleep disturbance, judgment/impulsivity, and irritability/hostility as major components of psychiatric symptoms in acute mania or mixed episodes in a series of trials of antipsychotics. However, it is unknown whether these factors predict treatment outcome. METHODS: Data from six double-blind, randomized, controlled clinical trials with aripiprazole in acute manic or mixed episodes in adults with bipolar I disorder were pooled for this analysis and the previously identified factors were examined for their value in predicting treatment outcome. Treatment efficacy was assessed for aripiprazole (n = 1,001), haloperidol (n = 324), lithium (n = 155), and placebo (n = 694) at baseline, days 4, 7, and 10, and then weekly to study end. Mean change in factor scores from baseline to week 3 was assessed by receiver operating characteristics curves for percentage factor change at day 4 and week 1. RESULTS: Subjects receiving aripiprazole, haloperidol, and lithium significantly improved mania factor scores versus placebo. Factors most predictive of endpoint efficacy for aripiprazole were judgment/impulsivity at day 4 and mania at week 1. Optimal factor score improvement for outcome prediction was approximately 40% to 50%. Early efficacy predicted treatment outcome across all factors; however, response at week 1 was a better predictor than response at day 4. CONCLUSIONS: This analysis confirms clinical benefits in early treatment/assessment for subjects with bipolar mania and suggests that certain symptom factors in mixed or manic episodes may be most predictive of treatment response.","urldate":"2015-05-10","journal":"International journal of bipolar disorders","author":[{"propositions":[],"lastnames":["Ostacher"],"firstnames":["Michael","J"],"suffixes":[]},{"propositions":[],"lastnames":["Suppes"],"firstnames":["Trisha"],"suffixes":[]},{"propositions":[],"lastnames":["Swann"],"firstnames":["Alan","C"],"suffixes":[]},{"propositions":[],"lastnames":["Eudicone"],"firstnames":["James","M"],"suffixes":[]},{"propositions":[],"lastnames":["Landsberg"],"firstnames":["Wally"],"suffixes":[]},{"propositions":[],"lastnames":["Baker"],"firstnames":["Ross","A"],"suffixes":[]},{"propositions":[],"lastnames":["Carlson"],"firstnames":["Berit","X"],"suffixes":[]}],"month":"January","year":"2015","pmid":"25945321","pages":"11","bibtex":"@article{ostacher_patterns_2015,\n\ttitle = {Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania.},\n\tvolume = {3},\n\tissn = {2194-7511},\n\turl = {http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4418976&tool=pmcentrez&rendertype=abstract},\n\tdoi = {10.1186/s40345-015-0026-0},\n\tabstract = {BACKGROUND: A previous factor analysis of Young Mania Rating Scale and Montgomery-Åsberg Depression Rating Scale items identified composite factors of depression, mania, sleep disturbance, judgment/impulsivity, and irritability/hostility as major components of psychiatric symptoms in acute mania or mixed episodes in a series of trials of antipsychotics. However, it is unknown whether these factors predict treatment outcome.\n\nMETHODS: Data from six double-blind, randomized, controlled clinical trials with aripiprazole in acute manic or mixed episodes in adults with bipolar I disorder were pooled for this analysis and the previously identified factors were examined for their value in predicting treatment outcome. Treatment efficacy was assessed for aripiprazole (n = 1,001), haloperidol (n = 324), lithium (n = 155), and placebo (n = 694) at baseline, days 4, 7, and 10, and then weekly to study end. Mean change in factor scores from baseline to week 3 was assessed by receiver operating characteristics curves for percentage factor change at day 4 and week 1.\n\nRESULTS: Subjects receiving aripiprazole, haloperidol, and lithium significantly improved mania factor scores versus placebo. Factors most predictive of endpoint efficacy for aripiprazole were judgment/impulsivity at day 4 and mania at week 1. Optimal factor score improvement for outcome prediction was approximately 40\\% to 50\\%. Early efficacy predicted treatment outcome across all factors; however, response at week 1 was a better predictor than response at day 4.\n\nCONCLUSIONS: This analysis confirms clinical benefits in early treatment/assessment for subjects with bipolar mania and suggests that certain symptom factors in mixed or manic episodes may be most predictive of treatment response.},\n\turldate = {2015-05-10},\n\tjournal = {International journal of bipolar disorders},\n\tauthor = {Ostacher, Michael J and Suppes, Trisha and Swann, Alan C and Eudicone, James M and Landsberg, Wally and Baker, Ross A and Carlson, Berit X},\n\tmonth = jan,\n\tyear = {2015},\n\tpmid = {25945321},\n\tpages = {11},\n}\n\n","author_short":["Ostacher, M. J","Suppes, T.","Swann, A. C","Eudicone, J. M","Landsberg, W.","Baker, R. A","Carlson, B. X"],"key":"ostacher_patterns_2015","id":"ostacher_patterns_2015","bibbaseid":"ostacher-suppes-swann-eudicone-landsberg-baker-carlson-patternsofresponsetoaripiprazolelithiumhaloperidolandplaceboacrossfactorscoresofmania-2015","role":"author","urls":{"Paper":"http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4418976&tool=pmcentrez&rendertype=abstract"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/asrommel","dataSources":["J8fbWsdsy3xAaB3pX"],"keywords":[],"search_terms":["patterns","response","aripiprazole","lithium","haloperidol","placebo","factor","scores","mania","ostacher","suppes","swann","eudicone","landsberg","baker","carlson"],"title":"Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania.","year":2015}